vs
Side-by-side financial comparison of LENSAR, Inc. (LNSR) and Laird Superfood, Inc. (LSF). Click either name above to swap in a different company.
LENSAR, Inc. is the larger business by last-quarter revenue ($14.3M vs $13.3M, roughly 1.1× Laird Superfood, Inc.). LENSAR, Inc. runs the higher net margin — -10.2% vs -13.2%, a 3.0% gap on every dollar of revenue. On growth, Laird Superfood, Inc. posted the faster year-over-year revenue change (15.0% vs -3.3%). Over the past eight quarters, LENSAR, Inc.'s revenue compounded faster (28.8% CAGR vs 16.1%).
LENSAR, Inc. is a medical technology company specializing in the development and commercialization of advanced ophthalmic surgical systems. Its proprietary augmented reality-enabled devices deliver high precision for cataract surgery and refractive lens exchange procedures, distributed to ophthalmology clinics, surgical centers and hospitals across North America, Europe and key Asia-Pacific markets.
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
LNSR vs LSF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.3M | $13.3M |
| Net Profit | $-1.5M | $-1.8M |
| Gross Margin | 36.6% | 34.1% |
| Operating Margin | -34.3% | -13.5% |
| Net Margin | -10.2% | -13.2% |
| Revenue YoY | -3.3% | 15.0% |
| Net Profit YoY | 92.2% | -341.4% |
| EPS (diluted) | $-0.09 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $14.3M | $13.3M | ||
| Q3 25 | $12.8M | $12.9M | ||
| Q2 25 | $12.3M | $12.0M | ||
| Q1 25 | $12.3M | $11.7M | ||
| Q4 24 | $14.8M | $11.6M | ||
| Q3 24 | $11.8M | $11.8M | ||
| Q2 24 | $10.7M | $10.0M | ||
| Q1 24 | $8.6M | $9.9M |
| Q4 25 | $-1.5M | $-1.8M | ||
| Q3 25 | $-3.7M | $-975.1K | ||
| Q2 25 | $-1.8M | $-362.2K | ||
| Q1 25 | $-27.3M | $-156.2K | ||
| Q4 24 | $-18.7M | $-398.4K | ||
| Q3 24 | $-1.5M | $-166.1K | ||
| Q2 24 | $-9.0M | $-239.1K | ||
| Q1 24 | $-2.2M | $-1.0M |
| Q4 25 | 36.6% | 34.1% | ||
| Q3 25 | 35.1% | 36.5% | ||
| Q2 25 | 43.8% | 39.9% | ||
| Q1 25 | 42.7% | 41.9% | ||
| Q4 24 | 35.1% | 38.6% | ||
| Q3 24 | 38.4% | 43.0% | ||
| Q2 24 | 45.5% | 41.8% | ||
| Q1 24 | 43.0% | 40.0% |
| Q4 25 | -34.3% | -13.5% | ||
| Q3 25 | -59.4% | -7.7% | ||
| Q2 25 | -51.2% | -3.3% | ||
| Q1 25 | -47.2% | -1.9% | ||
| Q4 24 | -8.7% | -4.1% | ||
| Q3 24 | -10.5% | -2.3% | ||
| Q2 24 | -49.4% | -3.4% | ||
| Q1 24 | -33.0% | -11.0% |
| Q4 25 | -10.2% | -13.2% | ||
| Q3 25 | -29.1% | -7.6% | ||
| Q2 25 | -14.4% | -3.0% | ||
| Q1 25 | -222.8% | -1.3% | ||
| Q4 24 | -126.2% | -3.4% | ||
| Q3 24 | -12.7% | -1.4% | ||
| Q2 24 | -84.6% | -2.4% | ||
| Q1 24 | -25.0% | -10.3% |
| Q4 25 | $-0.09 | — | ||
| Q3 25 | $-0.31 | — | ||
| Q2 25 | $-0.15 | — | ||
| Q1 25 | $-2.32 | — | ||
| Q4 24 | $-1.62 | — | ||
| Q3 24 | $-0.13 | — | ||
| Q2 24 | $-0.79 | — | ||
| Q1 24 | $-0.19 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.0M | $5.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-26.0M | $11.5M |
| Total Assets | $71.4M | $19.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.0M | $5.1M | ||
| Q3 25 | $16.9M | $5.1M | ||
| Q2 25 | $20.3M | $3.9M | ||
| Q1 25 | $25.2M | $7.0M | ||
| Q4 24 | $22.5M | $8.3M | ||
| Q3 24 | $18.1M | $7.9M | ||
| Q2 24 | $14.2M | $7.6M | ||
| Q1 24 | $17.9M | $7.1M |
| Q4 25 | $-26.0M | $11.5M | ||
| Q3 25 | $-25.9M | $12.8M | ||
| Q2 25 | $-23.1M | $13.4M | ||
| Q1 25 | $-22.1M | $13.3M | ||
| Q4 24 | $4.9M | $13.2M | ||
| Q3 24 | $22.7M | $13.1M | ||
| Q2 24 | $23.6M | $12.6M | ||
| Q1 24 | $31.8M | $12.7M |
| Q4 25 | $71.4M | $19.2M | ||
| Q3 25 | $70.2M | $18.9M | ||
| Q2 25 | $70.4M | $20.4M | ||
| Q1 25 | $73.0M | $21.5M | ||
| Q4 24 | $66.3M | $19.3M | ||
| Q3 24 | $62.0M | $18.8M | ||
| Q2 24 | $61.4M | $18.0M | ||
| Q1 24 | $66.1M | $17.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $618.0K | $68.4K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $618.0K | $68.4K | ||
| Q3 25 | $-3.5M | $1.2M | ||
| Q2 25 | $-5.0M | $-2.8M | ||
| Q1 25 | $-6.9M | $-1.3M | ||
| Q4 24 | $3.7M | $339.2K | ||
| Q3 24 | $3.2M | $305.8K | ||
| Q2 24 | $-3.8M | $642.7K | ||
| Q1 24 | $-5.3M | $-422.3K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-5.1M | — | ||
| Q1 25 | $-6.9M | — | ||
| Q4 24 | $3.7M | — | ||
| Q3 24 | $3.1M | — | ||
| Q2 24 | $-3.9M | — | ||
| Q1 24 | $-5.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -41.3% | — | ||
| Q1 25 | -56.6% | — | ||
| Q4 24 | 24.7% | — | ||
| Q3 24 | 26.5% | — | ||
| Q2 24 | -36.4% | — | ||
| Q1 24 | -61.6% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 0.2% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LNSR
| Products | $12.7M | 89% |
| Services | $1.6M | 11% |
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
